{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:01Z","timestamp":1793924461730,"version":"4.8.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["4646672"],"award-info":[{"award-number":["4646672"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["B29C20000360005"],"award-info":[{"award-number":["B29C20000360005"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejmech.2022.114971","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T11:15:23Z","timestamp":1669634123000},"page":"114971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Recent advances in PI3K\/PKB\/mTOR inhibitors as new anticancer agents"],"prefix":"10.1016","volume":"246","author":[{"given":"Maria Antonietta","family":"Occhiuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernando","family":"Lico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Ioele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6154-4330","authenticated-orcid":false,"given":"Fedora","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114971_bib1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14737140.2019.1674142","article-title":"The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Merz","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2022.114971_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib3","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12154-008-0008-0","article-title":"Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules","volume":"1","author":"Gunn","year":"2008","journal-title":"J. Chem. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114971_bib5","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.3390\/molecules27113412","article-title":"A review of twenty years of research on the regulation of signaling pathways by natural products in breast cancer","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114971_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5871188","article-title":"The involvement of WDHD1 in the occurrence of esophageal cancer as a downstream target of PI3K\/AKT pathway","author":"Xian","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbcan.2015.07.003","article-title":"PDK1: a signaling hub for cell migration and tumor invasion","volume":"1856","author":"Gagliardi","year":"2015","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2022.114971_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/cancers9030025","article-title":"Serine\/threonine kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) as a key regulator of cell migration and cancer dissemination","volume":"9","author":"Di Blasio","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114971_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2019.04.002","article-title":"Phosphoinositide spatially free AKT\/PKB activation to all membrane compartments","volume":"72","author":"Thapa","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.ejmech.2022.114971_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1389557520666200117144701","article-title":"Carbazole derivatives as kinase-targeting inhibitors for cancer treatment","volume":"20","author":"Ceramella","year":"2020","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1186\/s12885-018-4654-5","article-title":"AKT isoform-specific expression and activation across cancer lineages","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22041743","article-title":"The role of mTOR signaling as a therapeutic target in cancer","volume":"22","author":"Popova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112820","article-title":"Research progress of mTOR inhibitors","volume":"208","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib15","doi-asserted-by":"crossref","first-page":"10294","DOI":"10.1021\/bi060976+","article-title":"The FRB domain of mTOR: NMR solution structure and inhibitor design","volume":"45","author":"Leone","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114971_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"Dibble","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2022.114971_bib17","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.molcel.2021.03.031","article-title":"The dynamic mechanism of 4E-BP1 recognition and phosphorylation by mTORC1","volume":"81","author":"B\u00f6hm","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2022.114971_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114498","article-title":"Contemporary mTOR inhibitor scaffolds to diseases breakdown: a patent review (2015\u20132021)","volume":"238","author":"Oleksak","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2022.114971_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2015.03.009","article-title":"Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies","volume":"20","author":"Zhu","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114971_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm501026z","article-title":"Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring","volume":"58","author":"Andrs","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib24","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/MCB.16.4.1722","article-title":"Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction","volume":"16","author":"Wymann","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114971_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11596-009-0412-x","article-title":"Wortmannin inhibits K562 lukemic cells by regulating PI3k\/Akt channel in vitro","volume":"29","author":"Wu","year":"2009","journal-title":"J. Huazhong Univ. Sci. Technol. - Med. Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients","volume":"59","author":"Janku","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2022.114971_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1535-7163.MCT-05-0149","article-title":"The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non\u2013small cell lung cancer xenografts","volume":"4","author":"Ihle","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib29","first-page":"337","article-title":"A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with metastatic colorectal carcinoma","volume":"15","author":"Bowles","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782065","article-title":"LY294002 is a promising inhibitor to overcome sorafenib resistance in FLT3-ITD mutant AML cells by interfering with PI3K\/akt signaling pathway","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.244.244","article-title":"A vascular targeted Pan PI-3 kinase inhibitor, SF1126 with activity against multiple myeloma in vivo","volume":"108","author":"De","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114971_bib32","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.3390\/ijms23084295","article-title":"The inhibitory response to PI3K\/AKT pathway inhibitors MK-2206 and Buparlisib is related to genetic differences in pancreatic ductal adenocarcinoma cell lines","volume":"23","author":"Ma","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of Copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2014.12.019","article-title":"Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma","volume":"136","author":"Matulonis","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib35","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/cas.13561","article-title":"Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer","volume":"109","author":"Tamura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib36","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1021\/jm4003632","volume":"56","author":"Ndubaku","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","article-title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","volume":"32","author":"Dent","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib39","doi-asserted-by":"crossref","first-page":"8345","DOI":"10.1021\/acs.jmedchem.2c00267","article-title":"Identification of NVP-CLR457 as an orally bioavailable non-CNS-penetrant pan-class IA phosphoinositol-3-kinase inhibitor","volume":"65","author":"Fairhurst","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543776.2021.1924150","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)","volume":"31","author":"Sabbah","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114971_bib41","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1074\/jbc.M112.379446","article-title":"Selective inhibition of phosphoinositide 3-kinase p110\u03b1 preserves lymphocyte function","volume":"288","author":"So","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cpdd.613","article-title":"Characterizing the sources of pharmacokinetic variability for TAK-117 (Serabelisib), an investigational phosphoinositide 3-kinase alpha inhibitor: a clinical biopharmaceutics study to inform development strategy","volume":"8","author":"Patel","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2022.114971_bib43","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","article-title":"A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K\u03b1 isoform inhibitor, in patients with advanced solid malignancies","volume":"23","author":"Juric","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2159-8290.CD-21-0072","article-title":"RTK-dependent inducible degradation of mutant PI3K\u03b1 drives GDC-0077 (Inavolisib) efficacy","volume":"12","author":"Song","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114971_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-PD4-14","article-title":"Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies","volume":"78","author":"Hong","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib46","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PS11-11","volume":"81","author":"Olivera","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/10781552221096413","article-title":"The efficacy and safety of alpelisib in breast cancer: a real-world analysis","author":"Miller","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejmech.2022.114971_bib50","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2217\/fon-2022-0045","article-title":"A phase III trial of alpelisib + trastuzumab \u00b1 fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer","volume":"18","author":"P\u00e9rez-Fidalgo","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biochi.2014.07.014","article-title":"Effect of 2-arachidonoylglycerol on myosin light chain phosphorylation and platelet activation: the role of phosphatidylinositol 3 kinase\/AKT pathway","volume":"105","author":"Signorello","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2022.114971_bib53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential roles of PI(3)K\u2013p110\u03b2 in cell growth, metabolism and tumorigenesis","volume":"454","author":"Jia","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114971_bib54","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1038\/s41388-020-01444-3","article-title":"Inactivation of endothelial cell phosphoinositide 3-kinase \u03b2 inhibits tumor angiogenesis and tumor growth","volume":"39","author":"Azad","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114971_bib55","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.bmcl.2012.01.092","article-title":"Synthesis and structure\u2013activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors","volume":"22","author":"Lin","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.2514","article-title":"A phase I\/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors","volume":"32","author":"Arkenau","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib57","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib58","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1016\/j.bmcl.2012.08.072","article-title":"Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K\u03b2 inhibitors","volume":"22","author":"Certal","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib59","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1021\/jm300241b","article-title":"Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3K\u03b2 inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-Deficient cancers","volume":"55","author":"Certal","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib60","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1021\/jm401642q","article-title":"Discovery and optimization of pyrimidone indoline amide PI3K\u03b2 inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers","volume":"57","author":"Certal","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib61","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.18632\/oncotarget.12742","article-title":"Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114971_bib62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.31044","article-title":"First-in-human trial of the PI3K\u03b2-selective inhibitor SAR260301 in patients with advanced solid tumors","volume":"124","author":"B\u00e9dard","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib63","doi-asserted-by":"crossref","first-page":"20207","DOI":"10.1039\/C9RA02649E","article-title":"Discovery of a novel phosphoinositide 3-kinase gamma (PI3K\u03b3) inhibitor against hematologic malignancies and theoretical studies on its PI3K\u03b3-specific binding mechanisms","volume":"9","author":"Zhu","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2022.114971_bib65","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm1284","article-title":"Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis","volume":"11","author":"Camps","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114971_bib66","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nchembio.957","article-title":"A selective inhibitor reveals PI3K\u03b3 dependence of TH17 cell differentiation","volume":"8","author":"Bergamini","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114971_bib67","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1016\/j.bmcl.2012.06.049","article-title":"SAR studies around a series of triazolopyridines as potent and selective PI3K\u03b3 inhibitors","volume":"22","author":"Bell","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib68","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/med.21770","article-title":"Targeting phosphatidylinositol 3\u2010kinase gamma (PI3K\u03b3): discovery and development of its selective inhibitors","volume":"41","author":"Zhu","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114971_bib69","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114971_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105900","article-title":"Development of PI3K inhibitors: advances in clinical trials and new strategies (Review)","volume":"173","author":"Meng","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib71","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.bmc.2018.03.002","article-title":"Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3K\u03b4) inhibitors","volume":"26","author":"Xin","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-3-319-91439-8_12","volume":"212","author":"Zirlik","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib73","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.bmcl.2013.06.052","article-title":"Identification of GNE-293, a potent and selective PI3K\u03b4 inhibitor: navigating in vitro genotoxicity while improving potency and selectivity","volume":"23","author":"Safina","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib74","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib75","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d\u2013targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114971_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib78","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2147\/COPD.S309303","article-title":"Exploring PI3K\u03b4 molecular pathways in stable COPD and following an acute exacerbation, two randomized controlled trials","volume":"16","author":"Begg","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.ejmech.2022.114971_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127457","article-title":"Research advances on selective phosphatidylinositol 3 kinase \u03b4 (PI3K\u03b4) inhibitors","volume":"30","author":"Sun","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib80","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","article-title":"The dual PI3K\u03b4\/CK1\u03b5 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells","volume":"4","author":"Maharaj","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2022.114971_bib81","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","article-title":"Umbralisib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib82","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K\/HDAC inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-018-0055-x","article-title":"Final results of a phase 1b study of the safety and efficacy of the PI3K\u03b4 inhibitor acalisib (GS-9820) in relapsed\/refractory lymphoid malignancies","volume":"8","author":"Kater","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2022.114971_bib84","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/00498254.2021.1923859","article-title":"Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans","volume":"51","author":"Yue","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2022.114971_bib85","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib86","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1523\/JNEUROSCI.1324-21.2021","article-title":"Dual PI3K\u03b4\/\u03b3 inhibitor duvelisib prevents development of neuropathic pain in model of paclitaxel-induced peripheral neuropathy","volume":"42","author":"Adamek","year":"2022","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114971_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of tenalisib (Rp6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory t-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114971_bib88","first-page":"2475","article-title":"AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon","volume":"7","author":"Zinda","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib89","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1021\/jm8004527","article-title":"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-\\{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase","volume":"51","author":"Heerding","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","article-title":"Mechanism and management of AKT inhibitor-induced hyperglycemia","volume":"15","author":"Crouthamel","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1535-7163.MCT-10-0760","article-title":"Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930","volume":"10","author":"Yap","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib92","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/ijo.2015.3306","article-title":"Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review)","volume":"48","author":"Nitulescu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib93","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10637-015-0241-7","article-title":"A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer","volume":"33","author":"Azaro","year":"2015","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejca.2021.09.040","article-title":"TAKTIC: a prospective, multicentre, uncontrolled, phase IB\/II study of LY2780301, a p70S6K\/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients","volume":"159","author":"Vicier","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib95","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm301024w","article-title":"Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors","volume":"55","author":"Blake","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib96","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/jcph.1942","article-title":"Population pharmacokinetics of Ipatasertib and its metabolite in cancer patients","volume":"61","author":"Yoshida","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114971_bib97","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/1535-7163.MCT-09-0986","article-title":"AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth","volume":"9","author":"Grimshaw","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib98","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib99","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1158\/1078-0432.CCR-11-3313","article-title":"AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity","volume":"18","author":"Yap","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib100","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-20-0700","article-title":"First-in-Human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors","volume":"26","author":"McLeod","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib101","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.1179","article-title":"Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells","volume":"6","author":"Yamaji","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2022.114971_bib102","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/1568026620666200224101808","article-title":"Akt pathway inhibitors","volume":"20","author":"Uko","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib103","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1021\/pr400455j","article-title":"Characterization of a chemical affinity probe targeting akt kinases","volume":"12","author":"Pachl","year":"2013","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib104","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.18632\/oncotarget.3128","article-title":"DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2","volume":"6","author":"Qin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114971_bib105","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib106","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-022-29655-0","article-title":"Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors","volume":"13","author":"Savill","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114971_bib107","article-title":"A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma","volume":"40","author":"Stover","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2022.114971_bib108","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/0008-5472.CAN-13-3652","article-title":"Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition","volume":"74","author":"Mimura","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib109","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s10637-021-01085-7","article-title":"Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase\/v-akt murine thymoma viral oncogene homolog gene mutations","volume":"39","author":"Lee","year":"2021","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/genes9090450","article-title":"Phosphorylation-dependent inhibition of Akt1","volume":"9","author":"Balasuriya","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2022.114971_bib111","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ijc.30457","article-title":"BAY 1125976, a selective allosteric AKT1\/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models","volume":"140","author":"Politz","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib112","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/molecules22040643","article-title":"An expedient total synthesis of triciribine","volume":"22","author":"Hu","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114971_bib113","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1080\/07328319908044621","article-title":"Acyclic sugar analogs of triciribine: lack of antiviral and antiproliferative activity correlate with low intracellular phosphorylation","volume":"18","author":"Porcari","year":"1999","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.ejmech.2022.114971_bib114","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/cdd.2010.63","article-title":"The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane","volume":"17","author":"Berndt","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2022.114971_bib115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/neuonc\/nor035","article-title":"Control of proliferation in astrocytoma cells by the receptor tyrosine kinase\/PI3K\/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies","volume":"13","author":"G\u00fcrsel","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib116","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001813-200302000-00011","article-title":"Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt\/PKB survival pathway","volume":"14","author":"Ruiter","year":"2003","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib117","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/pharmaceutics13081242","article-title":"Antitumor activity of nanoparticles loaded with PHT-427, a novel AKT\/PDK1 inhibitor, for the treatment of head and neck squamous cell carcinoma","volume":"13","author":"Yanes-D\u00edaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2022.114971_bib118","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1021\/jm070040e","article-title":"Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling","volume":"50","author":"Chao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib119","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1535-7163.MCT-07-0211","article-title":"Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT\/PKB: mechanistic involvement of AKT catalytic activation loop cysteines","volume":"6","author":"Toral-Barza","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib120","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/jm900075g","article-title":"Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine","volume":"52","author":"Salaski","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib121","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/ml500088x","article-title":"Phenylalanine-based inactivator of AKT kinase: design, synthesis, and biological evaluation","volume":"5","author":"Nguyen","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2016.06.004","article-title":"PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3K\u03b1 inhibition","volume":"30","author":"Castel","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114971_bib123","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1074\/jbc.M110.156463","article-title":"Genetic and pharmacological inhibition of PDK1 in cancer cells","volume":"286","author":"Nagashima","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib124","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/srep26142","article-title":"A small molecule inhibitor of PDK1\/PLC\u03b31 interaction blocks breast and melanoma cancer cell invasion","volume":"6","author":"Raimondi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114971_bib126","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/sj.bjc.6605408","article-title":"A novel inhibitor of the PI3K\/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate","volume":"102","author":"Falasca","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib127","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/1535-7163.MCT-09-0985","article-title":"Molecular pharmacology and antitumor activity of PHT-427, a novel Akt\/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor","volume":"9","author":"Meuillet","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/13543776.2019.1597852","article-title":"A patent update on PDK1 inhibitors (2015-present)","volume":"29","author":"Sestito","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114971_bib129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4155\/ppa.12.17","article-title":"PDK1 inhibitors","volume":"1","author":"Barile","year":"2012","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejmech.2022.114971_bib130","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41416-019-0707-z","article-title":"Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer","volume":"122","author":"Mull","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092444","article-title":"ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays","volume":"9","author":"Guzm\u00e1n","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114971_bib132","doi-asserted-by":"crossref","first-page":"19867","DOI":"10.1074\/jbc.M501367200","article-title":"Novel small molecule inhibitors of 3-Phosphoinositide-dependent kinase-1","volume":"280","author":"Feldman","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib133","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.2174\/0929867329666220224112042","article-title":"The mTOR\/4E-BP1\/eIF4E signalling pathway as a source of cancer drug targets","volume":"29","author":"Maracci","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib134","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/cmdc.202100332","article-title":"Chemical and structural strategies to selectively target mTOR kinase","volume":"16","author":"Borsari","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114971_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112391","article-title":"Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors","volume":"199","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib136","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000398","article-title":"Final results of a phase I\/II trial of the combination bendamustine and rituximab with temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma","volume":"4","author":"Hess","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejmech.2022.114971_bib137","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1535-7163.MCT-10-0792","article-title":"Ridaforolimus (AP23573; MK-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","volume":"10","author":"Rivera","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib138","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114971_bib139","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114971_bib140","first-page":"8","article-title":"Current development of the second generation of mTOR inhibitors as anticancer agents","volume":"31","author":"Zhou","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib141","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","article-title":"Pushing the envelope in the mTOR pathway: the second generation of inhibitors","volume":"10","author":"Vilar","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib142","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib143","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yexcr.2018.02.032","article-title":"Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo","volume":"365","author":"Xu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib144","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and efficacy of the mTOR inhibitor, Vistusertib, combined with anastrozole in patients with hormone Receptor\u2212Positive recurrent or metastatic endometrial cancer","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib145","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bjc.2012.368","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma","volume":"107","author":"Naing","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib146","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/neuonc\/not139","article-title":"The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells","volume":"16","author":"Kahn","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib147","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/annonc\/mdw669","article-title":"Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1\/2 inhibition","volume":"28","author":"Kim","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib148","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1158\/0008-5472.CAN-12-3516","article-title":"Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition","volume":"73","author":"Nam","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib149","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ddstr.2009.12.001","article-title":"mTOR mediated anti-cancer drug discovery","volume":"6","author":"Liu","year":"2009","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.ejmech.2022.114971_bib150","article-title":"Preclinical evaluation of the dual mTORC1\/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma","volume":"915","author":"Zhang","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114971_bib151","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41416-020-01041-x","article-title":"Phase 1 study of mTORC1\/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","volume":"123","author":"Voss","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib152","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.18632\/aging.101155","article-title":"Gerosuppression by pan-mTOR inhibitors","volume":"8","author":"Leontieva","year":"2016","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2022.114971_bib153","doi-asserted-by":"crossref","first-page":"26230","DOI":"10.18632\/oncotarget.4579","article-title":"OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo","volume":"6","author":"Zhi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114971_bib154","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1158\/1535-7163.MCT-14-1052","article-title":"CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization","volume":"14","author":"Mortensen","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib155","first-page":"1","article-title":"Pharmacological inhibition of mTORC2 reduces migration and metastasis in melanoma","volume":"22","author":"Guenzle","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176599","article-title":"Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma","volume":"12","author":"Benavides-Serrato","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114971_bib157","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/cas.14395","article-title":"Potential new therapy of Rapalink\u20101, a new generation mammalian target of rapamycin inhibitor, against sunitinib\u2010resistant renal cell carcinoma","volume":"111","author":"Kuroshima","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114971_bib158","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114971_bib159","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543776.2021.1940137","article-title":"A patent review of mTOR inhibitors for cancer therapy (2011\u20132020)","volume":"31","author":"Qiu","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114971_bib160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/CAD.0000000000000354","article-title":"RES-529: a PI3K\/AKT\/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes","volume":"27","author":"Weinberg","year":"2016","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib161","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ijc.28126","article-title":"Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2","volume":"133","author":"Lin","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114971_bib162","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.1158\/0008-5472.CAN-08-2058","article-title":"Palomid 529, a novel small-molecule drug, is a TORC1\/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability","volume":"68","author":"Xue","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib163","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2022.114971_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.875372","article-title":"Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114971_bib165","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1158\/1535-7163.MCT-08-1200","article-title":"Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941","volume":"8","author":"Raynaud","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127258","article-title":"Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE","volume":"30","author":"Luo","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib167","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1016\/j.bmcl.2004.09.060","article-title":"Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries","volume":"14","author":"Leahy","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib168","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib169","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.bmcl.2010.03.046","article-title":"Identification of GNE-477, a potent and efficacious dual PI3K\/mTOR inhibitor","volume":"20","author":"Heffron","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib170","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1158\/1078-0432.CCR-18-3049","article-title":"The dual PI3K\/mTOR pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases","volume":"25","author":"Ippen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib171","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of clinical development candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib172","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrd.2016.134","article-title":"Bivalent mTOR inhibitors - the next generation","volume":"15","author":"Flemming","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114971_bib173","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/ci500493m","article-title":"Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602","volume":"54","author":"Poulsen","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2022.114971_bib174","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1535-7163.MCT-12-0466","article-title":"VS-5584, a novel and highly selective PI3K\/mTOR kinase inhibitor for the treatment of cancer","volume":"12","author":"Hart","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib175","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/acsmedchemlett.8b00167","article-title":"Discovery of an orally bioavailable dual PI3K\/mTOR inhibitor based on sulfonyl-substituted morpholinopyrimidines","volume":"9","author":"Shen","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib176","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1021\/jm9014982","article-title":"Lead optimization of n-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitors: discovery of PKI-402","volume":"53","author":"Dehnhardt","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib177","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-09-0954","article-title":"Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor","volume":"9","author":"Mallon","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib178","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/15384047.2018.1470733","article-title":"Preclinical evaluation of novel PI3K\/mTOR dual inhibitor SN202 as potential anti-renal cancer agent","volume":"19","author":"Wang","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2022.114971_bib179","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR kinase inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib180","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5\u2019-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib181","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1097\/HS9.0000000000000656","article-title":"A phase II study to assess the safety and efficacy of the dual mTORC1\/2 and PI3K inhibitor Bimiralisib (PQR309) in relapsed, refractory lymphoma","volume":"5","author":"Collins","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejmech.2022.114971_bib182","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112637","article-title":"Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K\/mTOR inhibitors","volume":"204","author":"Wu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib184","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","article-title":"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity","volume":"10","author":"Yuan","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051261","article-title":"PI3K\/mTOR dual inhibitor PF-04691502 is a schedule-dependent radiosensitizer for gastroenteropancreatic neuroendocrine tumors","volume":"10","author":"Chow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2022.114971_bib186","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-21-0301","article-title":"The PI3K\/mTOR inhibitor ompalisib suppresses nonhomologous end joining and sensitizes cancer cells to radio- and chemotherapy","volume":"19","author":"Du","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib187","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s13402-020-00514-8","article-title":"The PI3K\/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis","volume":"43","author":"Xiao","year":"2020","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib189","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1158\/1535-7163.MCT-13-0709","article-title":"Characterization of the activity of the PI3K\/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway","volume":"13","author":"Yu","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib190","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.2147\/OTT.S210128","article-title":"Dual PI3K\/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis","volume":"12","author":"Zhao","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2022.114971_bib191","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129556","article-title":"A dual PI3 kinase\/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines","volume":"1864","author":"Durrant","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2022.114971_bib194","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s13277-011-0290-2","article-title":"The dual PI3K\/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines","volume":"33","author":"Glienke","year":"2012","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2022.114971_bib195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-7-48","article-title":"NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity","volume":"7","author":"Fokas","year":"2012","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib196","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-15-0996","article-title":"Characterization of LY3023414, a novel PI3K\/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth","volume":"15","author":"Smith","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114971_bib197","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1158\/1078-0432.CCR-20-3242","article-title":"Preclinical evaluation and phase ib study of prexasertib, a chk1 inhibitor, and samotolisib (LY3023414), a dual PI3K\/mTOR inhibitor","volume":"27","author":"Hong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114971_bib198","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml300309h","article-title":"Discovery of the highly potent PI3K\/mTOR dual inhibitor PF-04979064 through structure-based drug design","volume":"4","author":"Cheng","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114971_bib199","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejmech.2016.06.030","article-title":"Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K\/mTOR inhibitor","volume":"122","author":"Han","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113109","article-title":"Omipalisib inspired macrocycles as dual PI3K\/mTOR inhibitors","volume":"211","author":"\u00c1lvarez","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114971_bib201","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ygyno.2019.01.012","article-title":"A novel PI3K\/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer","volume":"153","author":"Choi","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114971_bib202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00280-019-03918-y","article-title":"Preclinical efficacy of a novel dual PI3K\/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma","volume":"84","author":"Kim","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114971_bib203","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/13543780903066798","article-title":"Novel inhibitors of the PI3K family","volume":"18","author":"Carnero","year":"2009","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114971_bib204","first-page":"209","article-title":"From the bench to the bed side: PI3K pathway inhibitors in clinical development","volume":"347","author":"Maira","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2022.114971_bib205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbrc.2019.02.032","article-title":"Inhibition of gastric cancer cell growth by a PI3K-mTOR dual inhibitor GSK1059615","volume":"511","author":"Bei","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200873X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200873X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:46:06Z","timestamp":1759329966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342200873X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":199,"alternative-id":["S022352342200873X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114971","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in PI3K\/PKB\/mTOR inhibitors as new anticancer agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114971"}}